Dermatology

Raj Chovatiya, MD, PhD; Shawn Kwatra, MD; and Sarina B. Elmariah, MD, PhD, discuss the pathophysiology on PN and the role of type 1 inflammation in the disease.

Raj Chovatiya, MD, PhD; Shawn Kwatra, MD; and Sarina B. Elmariah, MD, PhD, provide an overview of prurigo nodularis (PN), its prevalence, and how it is a unique disease state to be differentiated from other disorders.

Brett King, MD, PhD, reviews how the drug class has altered the state of chronic skin disease management in this year alone.

Why patience is key following the major FDA decision earlier this year.

An interview on the SDPA 2022 presentation of Dr. Woolery-Lloyd in which she discusses dermatoses affecting patients of color.

A discussion with Dr. Markowitz on her presentation from SDPA 2022, during which she described various gaps in knowledge on skin health and future innovations she hoped to see.

New long-term phase 3 data show adults and adolescents both improved measures of quality of life when treated with either of 2 doses of ruxolitinib cream.

An interview with Dr. Markowitz on her presentation at SDPA 2022 presentation entitled ‘Skin of Color,’ regarding differentiating skin cancer from other conditions.

Findings from the ongoing LIBERTY AD OLE trial show the sustained long-term effect of the biologic therapy for eczema.

A discussion with Dr. Orozco on her SDPA 2022 presentation, discussing useful resources for physicians and PAs looking to get involved in the PAs Go Beyond campaign.

Online survey results show adults with psoriasis in specific areas may be treating and monitoring disease without clinician guidance—sometimes out of embarassment.

Long-term, real-world data show the IL-23 inhibitor benefits patient-reported measures of psychological wellbeing.

New data show adults receiving the biologic for eczema may see improvements in sleep disturbance within 4 weeks.

Post hoc analysis data from JADE REGIMEN show continuous and reduced-dose regimens provided similar efficacy and safety outcomes in the 2 age groups.

Phase 3 data suggest the novel twice-daily drug provides favorable efficacy and consistent safety over a regular regimen in patients aged 12 years and older.

Phase 3 data suggest children aged <6 months to 5 years old have benefit in itch relief and skin clearance as soon as 1 week into systemic therapy regimens.

New data from ECZTRA 1 and 2 show patients unable to achieve complete skin clearance nonetheless benefitted in at least 1 component of disease improvement.

An interview on several major highlights from Dr. Orozsco’s presentation about the greater visibility and importance of physician associates at SDPA 2022.

An interview with Dr. Orozco regarding her presentation at SDPA 2022 on the topic of physician associates and their value in the modern medical system.

An SDPA 2022 interview with Dr. Robert Kirsner regarding his presentation regarding the topic of wound healing and related changes in the field.

An interview at the SDPA 2022 Conference on major talking points from Dr. Robert Kirsner’s presentation on wound care with dermatologists and physician associates.

An interview from SDPA 2022 regarding highlights from Dr. Robert Kirsner’s presentation on dermatologists and wound healing.

Patients with psoriasis in high-impact areas may benefit from either of 2 available dosing regimens of the biologic.

Despite a Boxed Warning included in its 2017 FDA approval, the plaque psoriasis biologic was not linked to any causal cases of suicide attempts in 4-year, real-world data.

A recent research letter highlighted the importance of diversity in the field of dermatology, citing the lack of diversity among trainees in the field.